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SCIENTIFIC OPINION 
Scientific Opinion on the safety of refined Buglossoides oil as a novel food 
ingredient
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver a scientific opinion on refined Buglossoides oil as a novel food ingredient 
(NFI) in the context of Regulation (EC) No 258/97. The NFI is produced from the seeds of Buglossoides 
arvensis (L.) I. M. Johnst, using processes conventionally used for edible oil production. The main fatty acids 
(FAs) contained in the NFI are alpha-linolenic acid (ALA), stearidonic acid (SDA) and linoleic acid, with 
smaller amounts of oleic acid, gamma-linolenic acid (GLA) and saturated FAs. With the exceptions of SDA and 
GLA, these FAs are widely present in common foods. The NFI is intended to be used in a range of foods and 
food supplements to provide approximately 200 mg of SDA per day. Upon digestion, FAs are used primarily as 
an energy source. ALA and SDA can be elongated and desaturated to produce eicosapentaenoic acid. In human 
studies using various sources of SDA, no increase or small increases in SDA were observed in blood cell 
membranes or in total plasma. The proposed specifications for pyrrolizidine alkaloids and erucic acid, which are 
undesirable substances, do not give rise to concern in view of the proposed conditions of use. The available 
information does not give concerns as regards other undesirable substances in the NFI. Available animal studies 
provide only limited information on the safety of the NFI. Human studies that investigated different plant oils or 
fatty acid ethyl esters as sources of SDA, GLA and ALA found no adverse effects with up to 4 200 mg SDA/day 
for 12 weeks, up to 1 700 mg GLA/day for 28 days and 9 100 mg ALA/day for four weeks. The Panel concludes 
that the NFI is safe for the proposed uses and use levels. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver a scientific opinion on refined Buglossoides oil as a novel 
food ingredient (NFI) in the context of Regulation (EC) No 258/97, taking into account the comments 
and objections of a scientific nature raised by Member States. 
Refined Buglossoides oil is a triglyceride oil, in which the polyunsaturated fatty acids (PUFAs) alpha-
linolenic acid (ALA, 44 %), stearidonic acid (SDA, 20 %) and linoleic acid (13 %) are the main fatty 
acids (FAs), with smaller amounts of oleic acid, gamma-linolenic acid (GLA) and saturated FAs. With 
the exceptions of SDA and GLA, the main FAs present are widely present in common foods. The NFI 
is produced from seeds of Buglossoides arvensis (L.) I. M. Johnst. using processes conventionally 
used for edible oil production. 
With the exceptions of SDA and protein, the content specifications of refined Buglossoides oil are 
similar to those of refined Echium oil, which has previously been authorised in the EU as an NFI. 
The NFI is intended to be used in a range of foods and in food supplements to provide approximately 
200 mg of SDA per day. Based on consumption data of the UK national diet and nutrition survey, the 
highest mean and 97.5
th
 percentile intakes of SDA, on a per person basis, were calculated for male 
adults at 1 128 and 2 175 mg/day, respectively, while children had the lowest intake estimates, at 719 
and 1 351 mg/day. On a body weight basis, children were calculated to have the highest intake, with 
mean and 97.5
th
 percentile SDA intakes of 51 and 103 mg/kg body weight, respectively. 
Upon digestion, FAs are used primarily as an energy source. ALA and SDA can be elongated and 
desaturated to produce eicosapentaenoic acid. In human studies using various sources of SDA (750–
4 200 mg/day for 3–16 weeks), no increase or small increases in SDA levels were observed in the 
membranes of blood cells or in total plasma. 
Taking into account the composition of the oil and the proposed conditions of use, the Panel considers 
that consumption of the NFI is not nutritionally disadvantageous. 
The microbiological information provided does not give rise to any safety concerns. 
The proposed specifications for pyrrolizidine alkaloids and erucic acid, which are undesirable 
substances, do not give rise to concern in view of the proposed conditions of use. The Panel notes that 
the available information does not raise concerns as regards other undesirable substances in the NFI. 
Three animal feeding studies were carried out with the NFI. No adverse effects were seen in these 
studies. The Panel notes that these studies were not designed for toxicity testing. A number of animal 
studies were conducted using SDA- and/or GLA-containing oils from other sources or diets 
supplemented with SDA ethyl esters. No adverse effects were seen in any of these studies. The Panel 
notes that most studies were not designed for toxicity testing. The Panel also notes that a number of 
the animal studies provided were carried out in rodents. The Panel notes that desaturation and 
elongation of PUFAs are more pronounced in rodents than in humans and therefore extrapolation of 
results from studies in rodents to humans requires caution. Overall, the Panel considers that the 
available animal studies provide only limited information on the safety of the NFI. 
Human studies that investigated different plant oils or fatty acid ethyl esters as sources of SDA, GLA 
and ALA found no adverse effects with up to 4 200 mg SDA/day for 12 weeks, up to 1 700 mg 
GLA/day for 28 days and 9 100 mg ALA/day for four weeks. 
The Panel considers that the likelihood of adverse allergic reactions to the NFI is low. 
The Panel concludes that the NFI is safe under the proposed uses and use levels. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 28 
On 25 June 2013, the company Technology Crops International submitted a request in accordance 29 
with Article 4 of the Novel Food Regulation (EC) No 258/97
4
 to place on the market refined oil from 30 
the seeds of Buglossoides arvensis as a novel food ingredient (NFI). 31 
On 6 January 2014, the competent authorities of the United Kingdom forwarded to the Commission 32 
their initial assessment report, which came to the conclusion that refined oil from the seeds of 33 
Buglossoides arvensis meets the criteria for acceptance as a novel food defined in Article 3(1) of 34 
Regulation (EC) No 258/97. 35 
On 21 January 2014, the Commission forwarded the initial assessment report to the other Member 36 
States. Several of the Member States submitted comments or raised objections. 37 
In consequence, a decision is now required by the Commission under Article 7(1) of Regulation (EC) 38 
No 258/97. 39 
The concerns of a scientific nature raised by the Member States can be summarised as follows: 40 
 The analysis of polycyclic aromatic hydrocarbons (PAHs) was carried out using a method 41 
stipulating a detection limit of 2 µg/kg for benzo(a)pyrene. This method does not appear to be 42 
suitable for verifying compliance with the maximum permissible level of 2 µg/kg of 43 
benzo(a)pyrene for oils, as stipulated in Regulation (EC) No 1881/2006.
5
 In order to verify 44 
compliance, the limit of quantification of the method used should be at least 2 µg/kg. 45 
 Whether the testing facilities are accredited in accordance with an international system is not 46 
apparent from the documentation. 47 
 It was noted that the safety of the novel oil was fully based on the compositional resemblance to 48 
the authorised refined Echium oil which is derived from seeds of Echium Plantagineum. Although 49 
Buglossoides arvensis is taxonomically related to Echium Plantagineum, as both plants belong to 50 
the same Boraginaceae family, these are distinct species. 51 
 Buglossoides arvensis (L.) contains active substances such as pyrrolizidine alkaloids and has been 52 
described as having in vitro antigonadotropic activity. 53 
 With respect to the stability of the oil, studies were performed for only eight weeks at a maximum 54 
temperature of 60 °C, in darkness, in sealed vials and using nitrogen. In the event that these 55 
precautions against oxidation are not taken under the conditions of use of the oil, a study should be 56 
performed under the real storage conditions during the average expected life of the product. 57 
 During the processing of the foods for which the novel ingredient is intended, the temperatures 58 
reached can cause changes to the properties of the oil, which should also be investigated. 59 
 Some results of in vivo studies in mice and salmon, performed using oil from Buglossoides, are 60 
provided. From the information available, it is not possible to know whether good laboratory 61 
practice (GLP) or standardised (OECD) protocols have been followed. Only females were used in 62 
the research on mice, and there was no information on important indicators (consumption of food 63 
and water, haematology, clinical biochemistry, histopathology, etc.). 64 
                                                     
4 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and 
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6. 
5 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in 
foodstuff. OJ L 364, 20.12.2006, p. 5–24. 
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 Safety studies on individual components obtained from various sources or similar oils are also 65 
provided. In the case of gamma-linolenic acid, it is noted that the effect on the growth of the test 66 
animals differs according to the origin of the component. 67 
 None of the studies on humans were performed using the novel food ingredient, but rather using 68 
one of its components obtained from other sources or similar oils. 69 
 No toxicological information from studies in experimental animals nor data from investigations in 70 
humans were provided. The presence of possible harmful substances cannot be excluded based on 71 
the fact that the novel oil is highly purified, but requires additional safety studies. 72 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 73 
In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002,
6
 the European Commission asks 74 
the European Food Safety Authority to provide a scientific opinion by carrying out the additional 75 
assessment for refined oil from the seeds of Buglossoides arvensis as a novel food ingredient in the 76 
context of Regulation (EC) No 258/97. 77 
78 
                                                     
6 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general 
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in 
matters of food safety. OJ L 31, 1.2.2002, p. 1–24. 
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ASSESSMENT 79 
In accordance with Commission Recommendation 97/618/EC,
7
 refined oil from the seeds of 80 
Buglossoides arvensis (hereafter called refined Buglossoides oil) is allocated to Class 2.2, i.e. 81 
“complex NF from non-GM source. The source of the NF has no history of food use in the 82 
Community”. The assessment of the safety of this novel food ingredient (NFI) is based on data 83 
supplied in the original application, the initial assessment by the competent authority of the United 84 
Kingdom, the concerns and objections of the other Member States and the responses of the applicant. 85 
The data are required to comply with the information required for novel foods of Class 2.2, i.e. 86 
structured schemes I, II, III, IX, XI, XII and XIII of Commission Recommendation 97/618/EC. These 87 
structured schemes are addressed in Sections 1 to 7. The intention is to market refined Buglossoides 88 
oil for use in a range of foods and food supplements as a source of n-3 and n-6 polyunsaturated fatty 89 
acids (PUFAs). This assessment concerns only risks that might be associated with consumption, and is 90 
not an assessment of the efficacy of refined Buglossoides oil with regard to any claimed benefit. 91 
1. Specification of the NFI 92 
Buglossoides oil is a refined vegetable oil obtained from the seeds of Buglossoides arvensis (L.) I. M. 93 
Johnst.
8
 The specifications proposed by the applicant are presented in Table 1. Except for the content 94 
of the fatty acid stearidonic acid (SDA, C18:4(n-3)) and the protein content, the parameters and limits 95 
included in the specifications are the same as those set for “refined Echium oil”, an oil extracted from 96 
Echium plantagineum and previously authorised in the EU as a novel food ingredient in 2008.
9
 The 97 
applicant noted that Buglossoides arvensis is taxonomically related to Echium plantagineum, both 98 
being members of the Boraginoideae subfamily within the Boraginaceae family. According to the 99 
applicant, the taxonomic difference between the tribe containing Buglossoides (Lithospermeae) and 100 
the tribe containing Echium (Echieae) mainly relates to “their zygomorphic corolla with the stamens 101 
inserted at different heights”. 102 
Table 1:  Specifications of refined Buglossoides oil proposed by the applicant 103 
 Specification 
Description of Buglossoides 
oil 
The pale yellow product obtained by refining oil extracted from the seeds of 
Buglossoides arvensis (L.) I. M. Johnst. 
Stearidonic acid Not less than 15 % w/w of total fatty acids 
Trans fatty acids Not more than 2 % w/w of total fatty acids 
Acid value  Not more than 0.6 mg KOH/g  
Peroxide value Not more than 5 meq O2/kg 
Unsaponifiable content Not more than 2 %  
Protein content (total nitrogen) Not more than 10 µg/g 
Pyrrolizidine alkaloids Not detectable with a detection limit of 4 µg/kg  
The applicant provided analytical data from three non-consecutive batches of the NFI (Table 2). 104 
Batches NZ00053 and NZ00056 were produced using the cold press process and batch NZ00058 by 105 
extraction using hexane as the solvent. The three batches complied with the specifications.  106 
                                                     
7 Commission Recommendation 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientific 
aspects and the presentation of information necessary to support applications for the placing on the market of novel foods 
and novel food ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the 
European Parliament and of the Council. OJ L 253, 16.9.1997, p. 1–36. 
8 Taxonomic classification: Kingdom: Plantae; Phylum: Magnoliophyta; Class: Magnoliopsida; Order: Boraginales; 
Family: Boraginaceae; Genus: Buglossoides; Species: Buglossoides arvensis (L.) I. M. Johnst.  
9 Commission Decision of 27 June 2008 authorising the placing on the market of refined echium oil as novel food ingredient 
under Regulation (EC) No 258/97 of the European Parliament and of the Council (2008/558 EC). OJ L 180, 9.7.2008, 
p. 17–19. 
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Table 2:  Analytical data from three batches of refined Buglossoides oil  107 
                          Batch 
 NZ00053 NZ00056 NZ00058 Method 
Stearidonic acid (% w/w of total fatty acids) 20.5 19.7 20.8 AOCS Ce 1h-05 
Trans fatty acids (% w/w/ of total fatty acids) < 1.0 < 1.0 < 1.0 AOCS Ce 1h-05 
Acid value (mg KOH/g) 0.22 0.12 0.34 AOCS Ca 5a-40 
Peroxide value (meq O2/kg) 2.03 1.55 1.22 AOCS Cd 8-53 
Unsaponifiable content (%) 0.28 0.43 0.73 AOCS Ca 6a-40 
Protein content (total nitrogen) (µg/g) 1.3 1.0 1.3 Rigby et al. (2011) 
Pyrrolizidine alkaloids (µg/kg) < 1.0 < 1.0 < 1.0 Cramer et al. (2013) 
AOCS, American Oil Chemists’ Society. 108 
Buglossoides oil consists primarily of triglycerides (90 %) with small amounts of di- and 109 
monoglycerides, free fatty acids (2–6 %, 2–4 % and < 0.3 % respectively), and an unsaponifiable 110 
fraction (< 2 %). The unsaponifiable fraction comprises phytosterols, principally β-sitosterol, 111 
campesterol and stigmasterol, and γ-tocopherol. 112 
Alpha-linolenic acid (ALA), stearidonic acid (SDA) and linoleic acid (LA) are the major fatty acids in 113 
the oil. The fatty acid compositions of three batches of the NFI are provided in Table 3; they cover 114 
more than 98 % of the fatty acids present in the oil. 115 
Table 3:  Batch analysis of fatty acid composition of Buglossoides oil  116 
 % Composition of total fatty acids 
(a)
 
 NZ00053 NZ00056 NZ00058 Mean 
Alpha-linolenic acid (C18:3(n-3)) 44 44 43.5 43.8 
Stearidonic acid (C18:4(n-3)) 20.5 19.7 20.8 20.3 
Linoleic acid (C18:2(n-6)) 12.7 12.7 12.7 12.7 
Oleic acid (C18:1(n-9)) 7.6 7.6 7.5 7.6 
Gamma-linolenic acid (C18:3(n-6)) 6.4 6.2 6.3 6.3 
Palmitic acid (C16:0) 5.2 5.3 5.2 5.2 
Stearic acid (C18:0) 1.8 1.9 1.8 1.8 
Gondoic acid (C20:1(n-9)) 0.7 0.8 0.8 0.8 
Erucic acid (C22:1(n-9)) 0.2 0.2 0.2 0.2 
Lignoceric acid (C24:0) < 0.1 < 0.1 < 0.1 < 0.1 
Palmitoleic acid (C16:1(n-7)) 0.1 0 0.1 0.1 
Nervonic acid (C24:1(n-9)) 0.1 0 0 0 
 (a): Gas–liquid chromatography analysis, AOCS Ce 1h-05. 117 
The applicant noted that the composition of the NFI is similar to the composition of refined Echium 118 
oil, with the exception that the relative ratios of SDA and ALA are higher in the NFI. 119 
The NFI was analysed for protein content using the Bradford method and the 120 
combustion/chemiluminescence method. The protein contents in the three batches were below the 121 
limits of detection (10 ppm). Considering the limitations of the Bradford method for confirming the 122 
absence of protein (ACNFP, 2011), and the limited sensitivity of the combustion/chemiluminescence 123 
method, further analyses were performed using a method based on extraction using a borate buffer and 124 
protein quantification using 3-(4-carboxybenzoyl)quinolone-2-carboxaldehyde (Rigby et al., 2011). 125 
The results for the three batches were in the range 1.0–1.3 µg/g, which is below the maximum protein 126 
content of 10 µg/g set in the specifications of the NFI. 127 
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Trans fatty acids were not detected in any of the three batches analysed (limit of detection (LOD): 128 
1 %). A maximum limit of 2 % is set in the specifications. 129 
According to the specifications, the maximum peroxide value is 5 milliequivalent (meq) O2/kg which 130 
is below the maximum limit of up to 10 meq O2/kg oil for refined oils proposed by Codex 131 
Alimentarius (1999). Epoxy fatty acids were not detected in any of the three batches analysed (LOD: 132 
0.1 %). The applicant also provided the results of a p-anisidine test as a stability parameter. 133 
According to the specifications, the maximum acid value is 0.6 mg KOH/g which is the maximum 134 
limit for refined oils proposed by Codex Alimentarius (1999). 135 
Erucic acid is found in the NFI at levels of around 0.2 %, which is below the maximum level of 5 % in 136 
oils and fats intended for human consumption set by EU legislation.
10
 137 
Buglossoides arvensis synthesises pyrrolizidine alkaloids (PAs). The applicant reports that a sample of 138 
unrefined Buglossoides oil was found to contain a total of 44 µg/kg PAs, but refining reduced this 139 
level to below 1 µg/kg. A maximum limit of 4 µg/kg is set in the specification. The Panel on 140 
Contaminants in the Food Chain has evaluated the risks to human health related to the presence of PAs 141 
in food and concluded that 1,2-unsaturated PAs may act as genotoxic carcinogens in humans (EFSA 142 
CONTAM Panel, 2011). A benchmark dose lower confidence limit for a 10 % excess cancer risk of 143 
70 µg/kg body weight per day for the induction of liver haemangiosarcomas by lasiocarpine in male 144 
rats was calculated as the reference point for comparison with the estimated dietary exposure. 145 
Assuming a maximum PA content of 4 µg/kg in refined Buglossoides oil and an intake at the 97.5
th
 146 
percentile of 103 mg SDA/kg body weight per day, which is equivalent to 515 mg NFI/kg body 147 
weight per day, a child would be exposed to 2.1 × 10
–3
 µg PAs/kg body weight per day, which 148 
corresponds to a margin of exposure (MOE) of 34 000. 149 
The data on PA content, provided in Table 1 as part of the original application, were elaborated by a 150 
university research laboratory which specialises in this methodology. The applicant also provided data 151 
on additional analyses performed by the National Research Council Canada. The analysis of four 152 
batches, including NZ00056 and NZ00058, confirmed that traces of PAs were present at or above the 153 
limit of detection of 0.14 µg retronecine equivalents/kg; however, the contents were below the limit of 154 
quantification of 0.47 µg retronecine equivalents/kg. A full description of the analysis and the 155 
validation has been provided. 156 
The method was also used to investigate samples of crude and refined Buglossoides oils from different 157 
regions (UK, New Zealand and Canada). There were differences in the amounts of PAs in the crude 158 
oils (average 4.6–14.4 µg retronecine equivalents/kg); however, by comparing the content of the 159 
refined oil samples and the crude oil used as a source, a refining process including deodorisation and 160 
alkali wash was estimated to result in an approximately 25-fold reduction of the PA content. 161 
According to the applicant, commercial batches of Buglossoides oil will be subjected to at least one 162 
acid wash in addition to the other refining steps, as this has been demonstrated to result in further 163 
reductions in the PA content of between 32- and 1000-fold (Cramer et al., 2014). 164 
Finally, the applicant provided data on the analysis of individual PAs in Buglossoides oil performed in 165 
an accredited laboratory. None of 18 specific PAs was found (limit of quantification: 1 µg/kg) in cold 166 
pressed or extracted crude Buglossoides oils. 167 
Pesticide residues were not detected in analyses of the three batches of the NFI. 168 
The applicant provided analytical results of the three batches for heavy metals, dioxin and dioxin-like 169 
polychlorinated biphenyls (PCBs), and polycyclic aromatic hydrocarbons (PAHs), which were below 170 
                                                     
10 Council Directive 76/621/EEC of 20 July 1976 relating to the fixing of the maximum level of erucic acid in oils and fats 
intended as such for human consumption and in foodstuffs containing added oils or fats. OJ L 202, 28.7.1976, p. 1–4. 
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the maximum levels for contaminants in fats and oils set by EU legislation.11 Upon request from a 171 
Member State, the applicant contacted the laboratory which carried out the analysis for 172 
benzo(a)pyrene. It clarified that the limit of quantification was 2.0 µg/kg and that the detection limit 173 
was 0.6 µg/kg. The results of the three batches were below the limit of quantification. 174 
All analyses were carried out by laboratories which hold internationally recognised accreditations. 175 
The Panel considers that the information provided on the composition, the specification and the batch- 176 
to-batch variability of the NFI is sufficient and does not raise safety concerns. 177 
1.1. Stability 178 
The applicant indicated that authorised antioxidants may be added to the NFI, at levels compliant with 179 
EU legislation on food additives. 180 
In a stability study, samples of the three production batches were placed in sealed air-tight glass vials 181 
with nitrogen gas in the headspace, with or without the addition of 1 000 ppm of natural mixed 182 
tocopherols containing a minimum of 700 mg/g of d-γ-tocopherol as an antioxidant. Vials were stored 183 
at either 4 °C, 22 °C or 60 °C in the dark. After eight weeks, the peroxide values of all samples were 184 
found to be within specification. In response to a comment from a Member State, results after 12 185 
months were also provided by the applicant, which were compliant with the specification. 186 
According to the applicant, the storage condition of sealed vials purged with nitrogen closely mimics 187 
the storage conditions for bulk oil after manufacture and is a good model for oil packed in softgel 188 
capsules and for oil supplied in sealed bottles. For other uses as a food ingredient, the applicant 189 
indicates that the stability would have to be assessed individually for each product, as it would be 190 
affected by the particular combination of recipe, processing and packaging used and the presence of 191 
antioxidants. 192 
The Panel considers that these data provide sufficient information with respect to the stability of the 193 
NFI. 194 
2. Effect of the production process applied to the NFI 195 
The NFI is produced from the seeds of Buglossoides arvensis (L.) I. M. Johnst. Seeds are tested for 196 
purity, moisture and crop identity prior to manufacture. 197 
The oil may be extracted by expeller pressing or solvent extraction. 198 
In the first method, seeds are crushed or flaked and then passed through a screw press expeller. The 199 
temperature of the oil during the isolation step is normally in the range of 50–85 °C. The oil is 200 
collected, filtered and transferred to storage containers under nitrogen or another inert gas. The meal 201 
remaining after expeller pressing contains residual oil and is commonly re-extracted using solvent 202 
extraction. 203 
In the second method, seeds are lightly crushed or flaked and then immersed under nitrogen in an 204 
organic solvent (normally hexane or isohexane) at approximately 60 °C, which extracts the oil into 205 
solution. The oil/solvent mixture is decanted off, filtered and the solvent removed by evaporation 206 
followed by vacuum steam stripping. The oil is then transferred to storage containers. 207 
After extraction, crude Buglossoides oil is refined by methods commonly used in the edible oil 208 
industry, such as degumming, addition of sodium hydroxide to neutralise free fatty acids, bleaching, 209 
deodorisation and filtration. According to the applicant, commercial batches of Buglossoides oil will 210 
                                                     
11 Commission Regulation (EC) No 1881/2006 of 19 December 2006 setting maximum levels for certain contaminants in 
foodstuffs, OJ L 364, 20.12.2006, p.5. 
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be subjected to at least one acid wash in addition to the other refining steps, which has been 211 
demonstrated to result in a substantial reduction in the content of PAs (see Section 1). 212 
The finished oil is transferred to containers and the headspace is flushed with nitrogen prior to being 213 
sealed. 214 
Processing aids and food additives employed in the manufacture of the NFI are described in the 215 
application dossier. They meet food-grade specifications and are used in compliance with appropriate 216 
EU regulations. 217 
Manufacture is in conformance with current good manufacturing practices and with ISO 22000:2005, 218 
which incorporates the Hazard Analysis and Critical Control Points system. 219 
Once processing is complete, the oil is tested against the product specifications. The applicant also 220 
indicates that a sampling system for random batches of oil will be employed to monitor levels of 221 
undesirable substances such as PCBs, dioxins and pesticides. 222 
The applicant notes that any use of the oil will require the manufacturer to protect against exposure to 223 
air, especially if the oil is exposed to high temperatures, and the oxidation status of the oil will be 224 
tested in such cases to ensure that degradation has not taken place. For this reason, it will be 225 
recommended that the NFI should not be used for high-temperature cooking in the home (e.g. frying). 226 
A Member State requested information on the potential effects of high temperature on the properties 227 
of the oil. According to the applicant, changes in the configuration of the double bonds from cis to 228 
trans are negligible at temperatures below 220 °C. The Panel notes that some conjugated double bonds 229 
might be formed at these temperatures. The applicant indicates that processing temperatures are kept 230 
below this value. 231 
The manufacture of the NFI is based on procedures which are commonly employed in the production 232 
of edible oils. The Panel considers that the production process is sufficiently described and does not 233 
raise safety concerns. 234 
3. History of the organism used as a source 235 
Buglossoides arvensis was first described and classified as Lithospermum arvense by Linnaeus (1753). 236 
It has been described more recently by Clapham et al. (1962). The plant is native to the UK and is 237 
found in many parts of Europe and North America. The taxonomy of Buglossoides arvensis is 238 
described in Section 1. 239 
The applicant noted that Buglossoides oil has no history of use in food and, therefore, is not normally 240 
present in the diet. Other uses of the source are reported in Section 7.4. 241 
4. Anticipated intake/extent of use of the NFI 242 
The applicant intends to market the NFI for use in a range of foods and food supplements. The 243 
applicant’s aim is to provide approximately 200 mg of SDA per day. 244 
The applicant proposes that the NFI should be used in the same foods as those in which Echium oil is 245 
authorised, and in such proportions as to give the same maximum levels of SDA as those approved for 246 
Echium oil. The proposed uses and maximum levels of SDA are presented in Table 4. 247 
248 
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Table 4:  Intended uses of refined Buglossoides oil 249 
Use group Maximum level of stearidonic acid 
Milk-based products and drinkable yoghurt 
products delivered in a single dose  
250 mg/100 g; 75 mg/100 g for drinks 
Cheese preparations  750 mg/100 g 
Spreadable fat and dressings  750 mg/100 g 
Breakfast cereals  625 mg/100 g 
Food supplements  500 mg/day as recommended by the manufacturer 
Dietary foods for special medical purposes  in accordance with the particular nutritional requirements of 
the persons for whom the products are intended 
Foods intended for use in energy-restricted diets 
for weight reduction  
250 mg/meal replacement  
The applicant refers to the estimated intake of SDA from Echium oil which was provided in the 250 
application for the approval of refined Echium oil as an NFI (Croda Chemicals Europe Ltd., 2006) as a 251 
basis for estimating the intake of the NFI. Estimates were derived from consumption data of the UK 252 
national diet and nutrition survey (NDNS). 253 
Among the population groups, on a per person basis, the highest mean and 97.5
th
 percentile intakes of 254 
SDA of 1 128 and 2 175 mg/day, respectively, were calculated for male adults, while children had the 255 
lowest intake estimates at 719 and 1 351 mg/day (Table 5), respectively. 256 
Table 5:  Summary of the estimated daily intakes of SDA (NDNS data) 257 
Population 
group 
Age 
group 
(years) 
Users 
(%) 
Users 
(n) 
All person consumption 
(mg/day) 
All user consumption 
(mg/day) 
Mean P90 P95 P97.5 Mean P90 P95 P97.5 
Children 1.5–4.5 98.8 1 628 719 1 053 1 216 1 354 719 1 053 1 208 1 351 
Young people 4–10 99.6 834 860 1 234 1 371 1 561 860 1 245 1 374 1 561 
Female 
teenagers 
11–18 97.8 436 805 1 265 1 403 1 594 804 1 271 1 418 1 594 
Male teenagers 11–18 99.5 414 1 056 1 647 1 873 2 076 1 057 1 647 1 873 2 091 
Female adults 16–64 94.3 903 866 1 325 1 507 1 692 871 1 326 1 520 1 693 
Male adults 16–64 95.0 728 1 124 1 751 1 932 2 189 1 128 1 752 1 928 2 175 
P90, 90th percentile; P95, 95th percentile; P97.5, 97.5th percentile. 258 
On a body weight basis, children were calculated to have the highest intakes, at both the mean and 259 
97.5
th
 percentile, with SDA intakes of 51 and 103 mg/kg body weight, respectively (Table 6). 260 
Table 6:  Summary of the estimated daily intakes of SDA per kg body weight (NDNS data) 261 
Population 
group 
Age 
group 
(years) 
Users 
(%) 
Users 
(n) 
All person consumption 
(mg/kg body weight/day) 
All user consumption (mg/kg 
body weight/day) 
Mean P90 P95 P97.5 Mean P90 P95 P97.5 
Children 1.5–4.5 98.8 1 628 50 76 86 103 51 76 86 103 
Young people 4–10 99.6 834 34 51 58 68 34 51 58 68 
Female 
teenagers 
11–18 97.8 436 15 25 28 32 15 25 28 
32 
Male teenagers 11–18 99.5 414 20 32 35 39 20 32 35 39 
Female adults 16–64 94.3 903 12 20 23 26 13 20 23 26 
Male adults 16–64 95.0 728 13 22 24 28 14 22 25 28 
P90, 90th percentile; P95, 95th percentile; P97.5, 97.5th percentile. 262 
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The applicant notes that the estimated intakes represent an overestimate of the consumption of SDA 263 
from Buglossoides oil, because the estimates were based on a larger number of food groups than those 264 
which were included in the final authorisation for refined Echium oil and considered in the present 265 
application. 266 
The applicant also notes that both SDA and ALA levels will be comparable in foods containing the 267 
NFI and in foods containing Echium oil, but the added quantity of NFI will be lower as it contains 268 
higher concentrations of both fatty acids. 269 
5. Nutritional information on the NFI 270 
The applicant intends that the NFI will primarily be a replacement for Echium oil. The NFI has a 271 
higher proportion of SDA, so that less oil is required to provide the same intake of SDA. 272 
The main fatty acids contained in the NFI are the PUFAs ALA (44 % of the total fatty acid (TFA) 273 
content), SDA (20 %) and LA (13 %), respectively, with smaller amounts of oleic acid and gamma- 274 
linolenic acid (GLA), as described in Section 1. The saturated fatty acids palmitic acid and stearic acid 275 
represent 5 % and 2 % of the TFA content, respectively. Trans fatty acids represent less than 2 % of 276 
the TFA content, as per the NFI specifications. 277 
SDA can act as a precursor for eicosapentaenoic acid (EPA) (Section 7.1.1). With the exceptions of 278 
SDA and GLA, the main fatty acids present in the NFI are widely present in common foods. 279 
In its opinion on Dietary Reference Values for fats, the Panel set an Adequate Intake (AI) of 4 E % for 280 
LA and an AI of 0.5 E % for ALA (EFSA NDA Panel, 2010). No Tolerable Upper Intake Levels were 281 
set for those fatty acids. In view of the continuous relationship between saturated and trans fatty acid 282 
intake and increases in blood cholesterol concentrations, the Panel concluded that saturated and trans 283 
fatty acid intake should be as low as possible within the context of a nutritionally adequate diet. 284 
The intended use level of the NFI is 200 mg of SDA per day (Section 4), which would correspond to 285 
approximately 985 mg total fat, 430 mg ALA and 125 mg LA per day. 286 
At the proposed use level, the intake of palmitic acid and stearic acid would amount to approximately 287 
50 mg and 20 mg, respectively. At the maximum content of 2 %, this would correspond to an intake of 288 
20 mg trans fatty acids. These amounts are low compared with observed intakes of these fatty acids in 289 
European countries (EFSA NDA Panel, 2010) and are not considered a concern. 290 
Taking into account the composition of the oil and the proposed conditions of use, the Panel considers 291 
that consumption of the NFI is not nutritionally disadvantageous. 292 
6. Microbiological information on the NFI 293 
The processes used to extract and to refine the NFI include temperatures in excess of 90 °C under 294 
vacuum for tens of minutes, and filtration at the micron level. The oil itself has a very low water 295 
content and activity. The applicant has presented microbiological analyses confirming the absence of 296 
microbial contamination (yeasts, moulds, Enterobacteria and S. aureus) in three separate batches of 297 
the NFI. 298 
The Panel considers that the microbiological information provided does not raise safety concerns. 299 
7. Toxicological information on the NFI 300 
7.1. Absorption, distribution, metabolism and excretion 301 
The component fatty acids of the NFI are released from the glycerides upon digestion and are used 302 
primarily as an energy source. The fatty acids can also be metabolised to longer chain or more 303 
unsaturated fatty acids. ALA and SDA can be elongated and desaturated to produce EPA. 304 
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Some studies have investigated the metabolism of SDA in rodents (Huang et al., 1991; Yamazaki et 305 
al., 1992). The Panel notes that the ability to desaturate and elongate precursors of PUFAs is more 306 
pronounced in rodents than in humans and therefore extrapolation of results from studies in rodents to 307 
humans requires caution (Whelan, 2009; EFSA GMO Panel, 2014). 308 
In human subjects, the efficiency of conversion to EPA is greater with SDA than with ALA, as 309 
indicated by significantly higher increases in EPA concentrations in erythrocytes and plasma 310 
phospholipids obtained after SDA intake than after ALA intake (James et al., 2003). Efficiencies of 311 
conversion of SDA to EPA of between 3:1 and 6:1 have been reported, as measured by changes in the 312 
percentage of EPA in erythrocytes (James et al., 2003; Harris et al., 2008; Lemke et al., 2010). 313 
In human studies in which SDA (750–4 200 mg/day for 3–16 weeks) was administered in the form of 314 
SDA ethyl esters (James et al., 2003), Echium oil (Miles et al., 2004b; Surette et al., 2004) or SDA- 315 
enriched soybean oil (Harris et al., 2008; Lemke et al., 2010), no increase or only small increases in 316 
SDA were observed in the membranes of blood cells (erythrocytes, neutrophils and granulocytes) or in 317 
total plasma. 318 
7.2. Toxicity studies 319 
7.2.1. Studies with the NFI 320 
Three animal studies were carried out with the NFI. 321 
This included two mouse feeding studies, which aimed to investigate the effect of the NFI alone or in 322 
combination with a peptide preparation from hydrolysed milk protein on immunity parameters, 323 
mammary tumour development and the fatty acid composition of tissues (Surette and Matar, 2012; 324 
Surette, 2013). In the first period of both studies, mice received a control diet or a diet containing the 325 
NFI so that 1 % of energy was supplied as SDA (equivalent to 3 900 mg NFI/kg body weight per day 326 
and 780 mg SDA/kg body weight per day) for 28 and 56 days, respectively. In the second period, mice 327 
received the peptide preparation or a saline solution for (cycles of) seven days, with (study 2) or 328 
without (study 1) a challenge with mammary carcinoma cells. They were then sacrificed and tissues 329 
were processed for the various analyses. During the course of the studies, mice were inspected daily 330 
for “general health status”: respiration, colour of paws, muscle tone and signs of distress and 331 
dehydration. This inspection did not reveal any adverse effects in these two studies. 332 
In the third study, Atlantic salmon (Salmo salar L.) fry received a diet containing the NFI at a level of 333 
11.5 % or a control diet (containing herring oil) for 56 days (unpublished study report by Plante and 334 
Surette (2012). At the end of this period, fish condition, specific growth rate, mortality, per cent lipid 335 
deposited (plus fatty acid analysis) and gross energy content were assessed. No adverse effects were 336 
reported. 337 
The Panel considers that these studies were not designed for toxicity testing and thus provide only 338 
limited information on the safety of the NFI. 339 
7.2.2. Studies with other oils 340 
The applicant referred to a number of studies which investigated the effect of SDA- and/or GLA-rich 341 
oils from other sources or diets supplemented with SDA ethyl esters, in various species. 342 
7.2.2.1. Toxicity studies 343 
A 28-day gavage study and a sub-chronic 90-day feeding study combined with a one-generation 344 
reproduction toxicity study were conducted in rats using SDA-rich soybean oil (SDA content of 20 % 345 
and 26%, respectively), compliant with OECD guidelines (Hammond et al., 2008). No adverse effects 346 
were observed in these studies and the no-observed-adverse-effect-levels were 3 mL SDA-rich 347 
soybean oil/kg body weight per day (corresponding to approximately 600 mg SDA/kg body weight 348 
per day) and 4 000 mg SDA-rich soybean oil/kg body weight per day (corresponding to approximately 349 
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1 000 mg SDA/kg body weight per day), the highest doses tested in the respective studies (EFSA 350 
GMO Panel, 2014). 351 
Two longer-term toxicity studies with evening primrose oil in rats (dose of up to 2.5 mL evening 352 
primrose oil/kg body weight, corresponding to 230 mg GLA/kg body weight per day for 53 weeks) 353 
and beagle dogs (dose of up to 5 mL evening primrose oil/kg body weight, corresponding to 450 mg 354 
GLA/kg body weight per day for 52 weeks) did not reveal any adverse effects (Everett et al., 1988). 355 
The Panel notes that at the highest dose tested (corresponding to 1 000 mg SDA/kg body weight per 356 
day) SDA-rich soybean oil showed no adverse effects in a 90-day/one-generation reproduction feeding 357 
study in rats. Similarly, the highest dose of evening primrose oil tested in a 53-week toxicity study in 358 
rats (corresponding to 230 mg GLA/kg body weight per day) and a 52-week toxicity study in beagle 359 
dogs (corresponding to 450 mg GLA/kg body weight per day) did not show any adverse effects. 360 
7.2.2.2. Other feeding studies 361 
Other studies were conducted in rats (doses between 130 mg SDA/kg body weight per day for three 362 
months and 1 000 mg SDA ethyl esters/kg body weight per day for three weeks) (Yamazaki et al., 363 
1992; Engler, 1993; Barzanti et al., 1995), mice (2 000 mg SDA/kg body weight for three weeks) 364 
(Ishihara et al., 2002), guinea pigs (100 mg SDA/kg body weight per day for 40 days) (Crozier et al., 365 
1989) and beagle dogs (up to 193 mg SDA/kg body weight for 12 weeks) (Harris et al., 2007). 366 
Endpoints examined differed amongst studies and included food consumption, changes in body and 367 
liver weights, blood pressure, serum lipid concentrations, fatty acid composition of blood cells and 368 
tissues (liver and heart) and concentrations of inflammatory mediators. No adverse effects were 369 
reported. 370 
One study of rats which received various doses of GLA in the form of evening primrose oil, borage 371 
oil, blackcurrant oil and fungal oil (880, 2 090, 1 870, 2 860 mg GLA/kg body weight per day, 372 
respectively) or a control diet (sesame oil) did not find any significant effects of any treatment on body 373 
weight (Engler, 1993). A significant increase in serum cholesterol in the borage oil group compared 374 
with the sesame oil and fungal oil groups was reported. In a study of female mice, Wainwright et al. 375 
(2003) administered borage oil (containing 23 % GLA) or two types of genetically modified rapeseed 376 
oil (containing 23 or 36 % GLA, respectively) at doses corresponding to 3 400 to 5 400 mg GLA/kg 377 
body weight per day for six months. No treatment related-effects were found on reproductive-related 378 
outcomes. Reduced pup body weight associated with a slight increase in neonatal pup attrition was 379 
found in the groups receiving the rapeseed oils. There were no significant effects on pup behavioural 380 
development or on performance in plus maze tests. 381 
The Panel notes that animal feeding studies using oils from different plant sources of various fatty acid 382 
compositions as sources of SDA and/or GLA did not indicate any adverse effects at levels of up to 383 
2 000 mg SDA/kg body weight for three weeks and up to 5 400 mg GLA/kg body weight for six 384 
months in mice. These studies were not designed for toxicity testing and thus provide limited 385 
information on the safety of the NFI. 386 
7.3. Human studies 387 
The applicant referred to studies conducted in humans which investigated SDA, GLA and ALA. 388 
Sources used were SDA ethyl esters, SDA-rich soybean oil and Echium oil (containing a combination 389 
of SDA and GLA), borage oil (rich in GLA), and flaxseed oil or a blended oil (rich in ALA). 390 
One study found no effects of 1 500 mg SDA/day for six weeks, administered as SDA ethyl esters, on 391 
coagulation parameters, concentrations of immune markers and concentrations of blood lipids 392 
compared with similar doses of ALA or EPA ethyl esters (James et al., 2003). 393 
With respect to SDA- and GLA-rich oils, no adverse effects were found on the concentrations of blood 394 
lipids, blood pressure, heart rate, platelet function, standard blood laboratory tests and adverse events 395 
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recording in studies using SDA-rich soybean oil (doses of 3 700 mg SDA/day plus 1 200 mg GLA/day 396 
for 16 weeks and 4 200 mg SDA/day plus 1 100 mg GLA/day for 12 weeks) (Harris et al., 2008; 397 
Lemke et al., 2010) or Echium oil (doses of 1 900 mg SDA/day plus 1 700 mg GLA/day for 28 days 398 
and 1 000 mg SDA/day plus 900 mg GLA/day for 12 weeks) (Miles et al., 2004b; Miles et al., 2004a; 399 
Surette et al., 2004; Miles et al., 2006). 400 
Two studies which used ALA-rich flaxseed oil (dose of 20 000 mg ALA/day for 56 days and 401 
6 600 mg ALA/day for 16 weeks) or blended oil (9 100 mg ALA/day for four weeks) did not report 402 
any adverse effects on concentrations of blood lipids, coagulation parameters, blood pressure, heart 403 
rate, standard blood laboratory tests, urinalysis, or adverse events recording (Kelley et al., 1993; 404 
Takeuchi et al., 2007; Gracious et al., 2010). 405 
The Panel notes that human studies using oils from different plant sources of various fatty acid 406 
compositions as sources of SDA, GLA and/or ALA (up to 4 200 mg SDA/day for 12 weeks, up to 407 
1 700 mg GLA/day for 28 days and up to 9 100 mg ALA/day for four weeks) did not show any 408 
adverse effects. 409 
7.4. Possible presence of substances of concern 410 
Information on erucic acid and PAs is provided in Section 1. 411 
The applicant carried out a literature search in order to identify other possible undesirable substances 412 
in Buglossoides arvensis and related species. 413 
One in vitro study investigated the antigonadotropic activity of an aqueous extract from the roots of 414 
Lithospermum ruderale, a related species, on bovine steroid receptors (Findley and Jacobs, 1980). 415 
High concentrations of the extract (3.0 mg/mL uterine cytosol preparation) were required to displace 416 
progesterone, testosterone and oestradiol from their respective uterine receptors. Because of the high 417 
dose required and the different species, part of the plant and type of extract used, the Panel does not 418 
consider this relevant for the safety evaluation of the NFI. 419 
One review mentioned androgenic, gonadotropic and oestrogenic effects of the leaves and seeds of 420 
Lithospermum arvense [Buglossoides arvensis] (Sandroni, 2001). This review refers to a study in 421 
which a hot water extract of plant seeds was administered orally to rats (Ilarionov, 1989). The Panel 422 
considers that this report does not give rise to safety concerns regarding the NFI because the study was 423 
conducted with an aqueous extract. Water-soluble compounds are expected to partition into the 424 
aqueous phase during the extraction of the oil and to be largely removed from the oil in the course of 425 
the subsequent refining. 426 
One study investigated the distribution in plants of phytoecdysteroids, which are plant-produced 427 
analogues of steroidal insect hormones; the presence of these compounds was reported in the seeds 428 
and leaves of Buglossoides arvensis (Dinan et al., 2001). The Panel notes that phytoecdysteroids are 429 
polar molecules and considers that they would partition into the aqueous fractions during extraction 430 
and refining and are unlikely to be present in the refined oil. 431 
One review reported the presence of naphthoquinones (acetylshikonin, isobutyrylshikonin, 432 
isovalerylshikonin and beta-hydroxyisovalerylshikonin) in the roots of Lithospermum arvense 433 
[Buglossoides arvensis] (Papageorgiou et al., 1999). Shikonin and several related naphthoquinones 434 
have also been identified in the roots of Echium plantagineum (Weston et al., 2012). Shikonin 435 
derivatives extracted from the roots of Arnebia euchroma (Royle) Johnst. (Boraginaceae) were 436 
administered by gavage to Wistar rats at concentrations of 200, 400 and 800 mg/kg body weight per 437 
day for 90 days or 180 days (Su et al., 2013). Haematological and biochemical examinations were 438 
performed, and the vital organs were subjected to pathological analyses. No toxicity was observed. 439 
The applicant noted that shikonin biosynthesis is inhibited by light (Brigham et al., 1999; Yazaki et 440 
al., 2001) and that shikonin has been found only in roots of Buglossoides arvensis (Papageorgiou et 441 
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al., 1999). Considering that the oil is exclusively extracted from the seeds of Buglossoides arvensis, 442 
the Panel considers that naphthoquinones present in the roots of Buglossoides arvensis are not relevant 443 
for the safety assessment of the NFI. 444 
The applicant referred to the EFSA scientific cooperation (ESCO) report on a compendium of 445 
botanical species that have been reported to contain toxic, addictive, psychotropic or other substances 446 
of concern (EFSA, 2009). No entries relate to Buglossoides species. There are two entries relating to 447 
Lithospermum spp., which report the presence of PAs. No other substances of concern have been 448 
reported in any species of the Boraginaceae family. Several species have been traditionally used as 449 
foodstuffs or medicines (for instance, Borago officinalis (seed oil, flowers and leaf tea), Echium 450 
plantagineum (seed oil) and Symphytum officinale (leaf or root tea)). The Panel notes that an update of 451 
this compendium was published in 2012 (EFSA, 2012). No additional information of relevance for 452 
this assessment is provided in this update. 453 
The Panel notes that the available information does not raise concerns as regards undesirable 454 
substances in the NFI other than PAs and erucic acid. 455 
8. Allergenicity 456 
The applicant states that no allergic reactions to Buglossoides arvensis have been reported. No 457 
allergens of Buglossoides arvensis have been identified in the literature or in the Allergome 458 
database.
12
 459 
The Panel notes that Buglossoides oil is refined by methods commonly used in the edible oil industry 460 
(Section 2), which substantially reduce the protein content of the oil (Section1). 461 
Based on the limited data available, the Panel considers that allergic reactions to the NFI cannot be 462 
ruled out, but that the likelihood is low. 463 
DISCUSSION 464 
The oil obtained from Buglossoides arvensis (L.) is characterised by the presence of n-3 and n-6 465 
PUFAs. The high content of SDA, an intermediate in the synthesis of EPA, is a particular feature. 466 
With the exceptions of SDA and GLA, the main fatty acids present in the NFI are widely present in 467 
common foods. The applicant intends to use the NFI in a range of food products and in food 468 
supplements to provide approximately 200 mg of SDA per day. 469 
Upon digestion, the component fatty acids are released from the glycerides and are used primarily as 470 
an energy source. Fatty acids can also be metabolised to longer chain or more unsaturated fatty acids. 471 
ALA and SDA can be elongated and desaturated to produce EPA. In human studies in which SDA 472 
was administered in the form of SDA ethyl esters or SDA-rich oils at doses of between 750 and 473 
4 200 mg/day for 3–16 weeks, no increase or only small increases in SDA were observed in the 474 
membranes of blood cells or in total plasma. 475 
The compositional data provided demonstrate that the oil obtained from Buglossoides arvensis is 476 
similar to the oil obtained from the taxonomically related Echium plantagineum; refined Echium oil 477 
has already been authorised as an NFI. The specifications and uses of refined Buglossoides oil 478 
proposed by the applicant are similar to those specified for refined Echium oil. 479 
The compositional data provided for three batches of the NFI, the information on the production 480 
process and the proposed specifications are considered sufficient by the Panel and do not raise safety 481 
concerns. 482 
                                                     
12 http://www.allergome.org, consulted on 17 January 2013 
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The refining procedure applied results in a reduction of the content of PAs, a class of undesirable 483 
substances present in Buglossoides arvensis, to levels in the NFI below the maximum limit of 4 µg/kg 484 
as set in the specification, which corresponds to a MOE of 34 000 for children who have the highest 485 
exposure on a mg per kg body weight basis. 486 
Erucic acid is found in the NFI at levels of around 0.2 %, which is below the maximum level of 5 % in 487 
oils and fats intended for human consumption set by EU legislation. 488 
The refining procedure reduces the level of residual protein below the proposed limit of 10 µg/g set in 489 
the specifications. 490 
The Panel notes that the available information does not raise concerns as regards other undesirable 491 
substances in the NFI. 492 
Three animal feeding studies were carried out with the NFI. A number of animal studies were 493 
conducted using SDA- and/or GLA-containing oils from other sources or diets supplemented with 494 
SDA ethyl esters. No adverse effects were seen in any of these studies. The Panel notes that most 495 
studies were not designed for toxicity testing. The Panel also notes that a number of the animal studies 496 
provided were carried out in rodents. The Panel notes that the ability to desaturate and elongate 497 
precursors of PUFAs is more pronounced in rodents than in humans and therefore extrapolation of 498 
results from studies in rodents to humans requires caution. Overall, the Panel considers that available 499 
animal studies provide only limited information on the safety of the NFI. 500 
The applicant provided human studies that investigated different plant oils or fatty acid ethyl esters as 501 
sources of SDA, GLA and ALA, which are component fatty acids of the NFI. No adverse effects were 502 
reported with up to 4 200 mg SDA/day for 12 weeks, up to 1 700 mg GLA/day for 28 days and 503 
9 100 mg ALA/day for four weeks. 504 
CONCLUSIONS 505 
The Panel concludes that the novel food ingredient, refined Buglossoides oil, is safe under the 506 
proposed uses and use levels. 507 
DOCUMENTATION PROVIDED TO EFSA 508 
1. Dossier “Application for authorisation of refined Buglossoides oil as a novel food” received on 16 509 
June 2014. Submitted by Technology Crops Technology on 25 June 2013. Additional data were 510 
provided on 6 October 2014. 511 
2. Letter from the European Commission to the European Food Safety Authority with the request for 512 
a scientific opinion on refined oil from the seeds of Buglossoides arvensis as a novel food 513 
ingredient. SANCO/E6/AH/ks ref. Ares(2014)1898824, dated 11 June 2014. 514 
3. Initial assessment report carried out by the United Kingdom: “Opinion on an application under the 515 
novel foods regulation for refined oil from Buglossoides arvensis”, Advisory Committee on Novel 516 
Foods and Processes, Food Standards Agency. 517 
4. Member States’ comments and objections. 518 
5. Response by the applicant to the initial assessment report and the Member States’ comments and 519 
objections. 520 
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ABBREVIATIONS 649 
AI adequate intake 650 
ALA alpha-linolenic acid 651 
EPA eicosapentaenoic acid 652 
ESCO EFSA scientific cooperation 653 
FA fatty acid 654 
GLA gamma-linolenic acid 655 
LA linoleic acid 656 
LOD limit of detection 657 
MOE margin of exposure 658 
NDNS national diet and nutrition survey 659 
NFI novel food ingredient 660 
PA pyrrolizidine alkaloid 661 
PCB polychlorinated biphenyl 662 
PUFA polyunsaturated fatty acid 663 
SDA stearidonic acid 664 
TFA total fatty acid 665 
